(Q41871348)

13 October 2017

Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody (English)

1 reference

13 October 2017

1 reference

2

1 reference

13 October 2017

4

Darell D Bigner

1 reference

13 October 2017

Bryan D Choi

1

1 reference

13 October 2017

Luis Sanchez-Perez

series ordinal

3

1 reference

13 October 2017

John H Sampson

series ordinal

5

1 reference

13 October 2017

22 October 2013

1 reference

13 October 2017

1 reference

13 October 2017

2

1 reference

13 October 2017

12

1 reference

13 October 2017

e26757

1 reference

Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody

13 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891636

An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891636

Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891636

A novel bispecific antibody recruits T cells to eradicate tumors in the "immunologically privileged" central nervous system

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891636

Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891636

Bispecific antibodies engage T cells for antitumor immunotherapy

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891636

EGFRvIII-targeted vaccination therapy of malignant glioma

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891636

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891636

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891636

Human T regulatory cells can use the perforin pathway to cause autologous target cell death

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891636

Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891636

18 August 2018

Identifiers

DOI

10.4161/ONCI.26757

1 reference

13 October 2017

1 reference

13 October 2017

PubMed publication ID

24475376

1 reference